NSC logoThe cost of publication in Journal of Biomedical Science is borne by the National Science Council, Taiwan.

Open Access Research

Recombinant salmonella-based 4-1BBL vaccine enhances T cell immunity and inhibits the development of colorectal cancer in rats: in vivo effects of vaccine containing 4-1BBL

Jianxin Ye1, Ling Li1, Yuanting Zhang1, Xueguang Zhang2, Daming Ren3 and Weichang Chen1*

Author Affiliations

1 Department of Gastroenterology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China

2 Institute of Medical Biotechnology, Key Laboratory of Medicine and Clinical Immunology of Jiangsu Province, Soochow University, 215007, Suzhou, China

3 Institute of Genetics, State Key Laboratory of Genetic Engineering of Fudan University, 200433, Shanghai, China

For all author emails, please log on.

Journal of Biomedical Science 2013, 20:8 doi:10.1186/1423-0127-20-8

Published: 17 February 2013

Abstract

Background

Immunotherapy with vaccines is attractive for the treatment of cancer. This study is aimed at determining the effect of recombinant Salmonella (SL3261)-based 4-1BB ligand (4-1BBL) vaccine on the development of colorectal cancers and the potential immune mechanisms in rats.

Results

In comparison with that in the PBS group, similar levels of 4-1BBL expression, the frequency of T cells, IFN-γ responses, and comparable numbers of tumors were detected in the SL3261 and SL3261C groups of rats. In contrast, significantly fewer numbers of tumors, increased levels of 4-1BBL expression in the spleens and colorectal tissues, higher frequency of peripheral blood and splenic CD3+CD25+ T cells, and stronger splenic T cell IFN-γ responses were detected in the SL3261R group of rats.

Conclusion

Our results indicated that vaccination with recombinant attenuated Salmonella harboring the 4-1BBL gene efficiently enhanced T cell immunity and inhibited the development of carcinogen-induced colorectal cancers in rats.

Keywords:
Recombinant attenuated salmonella; Colorectal cancer; 4-1BBL; T cell-based cellular immunity